Krebs Biochemicals & Industries Ltd. (IN:KREBSBIO)
:KREBSBIO
KREBSBIO Stock Chart & Stats
₹71.00
-₹2.80(-2.89%)
At close: 4:00 PM EST
₹71.00
-₹2.80(-2.89%)
Day’s Range― - ―
52-Week Range₹38.52 - ₹113.90
Previous CloseN/A
Volume3.29K
Average Volume (3M)726.00
Market Cap
₹983.16M
Enterprise Value₹3.24B
Total Cash (Recent Filing)₹1.27M
Total Debt (Recent Filing)₹2.19B
Price to Earnings (P/E)―
Beta1.46
Next Earnings
May 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.45
Shares Outstanding21,560,587
10 Day Avg. Volume346
30 Day Avg. Volume726
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)-1.00
Price to Sales (P/S)3.37
P/FCF Ratio-12.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
B2B Manufacturing ModelA direct B2B manufacturing model serving industrial buyers implies recurring contract and supply relationships, predictable production needs, and clearer cost pass-through dynamics. Over 2–6 months this supports stable revenue channels if production and customer contracts remain intact.
Industry Exposure: Specialty & Generic DrugsOperating in the specialty and generic drug supply chain creates structural demand for biochemical inputs and benefits from stable pharmaceutical manufacturing needs. This industry positioning supports long-term demand resilience and potential for repeat B2B orders versus cyclical consumer markets.
Improving EPS TrendPositive EPS growth indicates operational improvements or cost control versus prior periods. If sustained, this trend can translate into incremental margin recovery and investor confidence, providing a foundation for stabilizing cash flows and financing options over the medium term.
Bears Say
Negative Equity / High LeverageNegative shareholders' equity and high leverage materially increase insolvency and refinancing risk. Over months this restricts access to debt and equity markets, forces expensive short-term funding or asset sales, and reduces strategic flexibility for capex or working capital support.
Persistent Negative Cash FlowSustained negative operating and free cash flow erodes liquidity and necessitates external financing to sustain operations. This structural cash conversion weakness undermines investment capacity, risks supplier relationships, and increases default probability absent durable turnaround or new capital.
Sustained Losses & Steep Revenue DeclineDeep revenue contraction and persistent net losses point to demand or competitive problems and poor cost absorption. Over a multi-month horizon this reduces economies of scale, pressures margins further, and complicates any recovery absent product mix, pricing, or market-share stabilization.
Krebs Biochemicals & Industries Ltd. News
KREBSBIO FAQ
What was Krebs Biochemicals & Industries Ltd.’s price range in the past 12 months?
Krebs Biochemicals & Industries Ltd. lowest stock price was ₹38.52 and its highest was ₹113.90 in the past 12 months.
What is Krebs Biochemicals & Industries Ltd.’s market cap?
Krebs Biochemicals & Industries Ltd.’s market cap is ₹983.16M.
When is Krebs Biochemicals & Industries Ltd.’s upcoming earnings report date?
Krebs Biochemicals & Industries Ltd.’s upcoming earnings report date is May 26, 2026 which is in 50 days.
How were Krebs Biochemicals & Industries Ltd.’s earnings last quarter?
Krebs Biochemicals & Industries Ltd. released its earnings results on Feb 09, 2026. The company reported -₹1.45 earnings per share for the quarter, missing the consensus estimate of N/A by -₹1.45.
Is Krebs Biochemicals & Industries Ltd. overvalued?
According to Wall Street analysts Krebs Biochemicals & Industries Ltd.’s price is currently Overvalued.
Does Krebs Biochemicals & Industries Ltd. pay dividends?
Krebs Biochemicals & Industries Ltd. does not currently pay dividends.
What is Krebs Biochemicals & Industries Ltd.’s EPS estimate?
Krebs Biochemicals & Industries Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Krebs Biochemicals & Industries Ltd. have?
Krebs Biochemicals & Industries Ltd. has 21,560,587 shares outstanding.
What happened to Krebs Biochemicals & Industries Ltd.’s price movement after its last earnings report?
Krebs Biochemicals & Industries Ltd. reported an EPS of -₹1.45 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.018%.
Which hedge fund is a major shareholder of Krebs Biochemicals & Industries Ltd.?
Currently, no hedge funds are holding shares in IN:KREBSBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Krebs Biochemicals & Industries Ltd.
Krebs Biochemicals & Industries Limited manufactures and sells active pharmaceutical ingredients in India. The company develops biotech processes for application in medicine, agriculture, and industry fields. Its products, such as androstenedione, lovastatin, and simvastatin for anti-cholesterol and steroid intermediate applications. The company is also developing various products, including amlodipine, cetirizine, orlistat, serratiopepetidase, telmisartan, and phenylephrine for anti-hypertension, anti-histamine, anti-obesity, anti-inflammatory, and cold and cough applications. In addition, it offers contract manufacturing services for large pharmaceutical and multinational companies. Krebs Biochemicals & Industries Limited was incorporated in 1991 and is headquartered in Hyderabad, India.
Technical Analysis
Aarey Drugs & Pharmaceuticals Ltd.
―
Alpa Laboratories Limited
―
Bafna Pharmaceuticals Limited
―
Bal Pharma Limited
―
Vaishali Pharma Ltd.
―